Lipid photosensitizers for suppression of gastric inhibitory polypeptide in obese with type 2 diabetes

Biomaterials. 2020 Jul:246:119977. doi: 10.1016/j.biomaterials.2020.119977. Epub 2020 Mar 26.

Abstract

"K-cell targeted photodynamic therapy (K-cell targeted PDT)" with a minimally invasive procedure was investigated to reduce the secretion of gastric inhibitory polypeptide (GIP), an incretin hormone secreted from enteroendocrine K-cells in the duodenum that is suspected to be strongly correlated with obesity. Oleic acid-poly (ethylene glycol)-chlorin e6 (OA-PEG-Ce6, OPC) was designed for PDT because it targets K-cells through the interaction of OA in OPC with a G protein-coupled receptor (GPR 119) that is overexpressed on K-cells and mediates fatty acid sensing. OPC interacted with duodenal cells (HUTU-80) expressing GPR 119 and HEK 293 cells transfected with human GPR 119 to mimic K-cells in vitro. The intracellular intensity and cytotoxicity of OPC on HUTU-80 cells increased 5- and 3-fold compared to PEG-Ce6, respectively. In particular, its intensity on HEK 293 cells overexpressing GPR 119 showed 7.8-fold higher than that of PEG-Ce6. Moreover, in high fat-diet animal models, OPC induced endocrine cell death through PDT, resulting in a decrease in the plasma GIP level and a reduction their weight (80% less than on the day of PDT initiation). Therefore, K-cell targeted PDT presents a new direction of future minimally invasive anti-obesity treatment to replace conventional methods such as bariatric surgery and radiofrequency ablation.

Keywords: Endo-laparoscopic photodynamic therapy; Gastric inhibitory polypeptide; K-cell; Obesity; Photosensitizer; Type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2*
  • Gastric Inhibitory Polypeptide
  • HEK293 Cells
  • Humans
  • Obesity
  • Photochemotherapy*
  • Photosensitizing Agents
  • Porphyrins*

Substances

  • Photosensitizing Agents
  • Porphyrins
  • Gastric Inhibitory Polypeptide